OTREXUP Update at Jefferies (Transcript)

Excerpts...

"And the first program of our own which we're developing a OTREXUP is really design the OTREXUP more useful in the management of rheumatoid arthritis patients. And I'll talk about that now. So this is OTREXUP, head of our sales and marketing organization is in the audience getting ready to launch this.

And what's interesting about this drug is it can be sold to a very highly effective focused audience, there is about 3,000 rheumatologists in this country. And we need 25 representatives to hit all of the high prescribers this area and this is part of that strategy to identify products where we can bring a meaningful clinical benefit to the product and then sell it into a very specialized area like rheumatology.

So for us this is a affordable product that we will be able to market and we're looking at product here which probably has sales potential is up $200 million range with 25 represent to as we looking at spending somewhere between $12 million and $15 million a year on sales and marketing expenses. So is affordable for a company like us."

Here's the link... http://www.earningsimpact.com/Transcript/81962/ATRS/Antares-Pharma-Inc---Jefferies-2013-Global-Healthcare-Conference